search icon
  • Print
  • ShareThis
  • Text Size


In order to contribute to the discussion forum you need to be an IDSA member. If you are an IDSA member, please login now. Please read our Discussion Forum Guidelines and Terms of Use before joining.

Hepatitis C

Welcome to Hepatitis C Management Discussion Board! The Hepatitis C Management Discussion Board provides Infectious Disease Clinicians a platform to connect with colleagues to exchange information, case studies, complications, and new developments on matters concerning hepatitis C treatment and management. Certain case studies will be developed into clinical vignettes and will be available to Infectious Disease Clinicians for future reference. Please be respectful of all participants and their respective comments. Please read our Terms of Use and Discussion Forum Guidelines.

 

Any diagnostic or therapeutic recommendations and all opinions presented are those of the individual contributor. They do not necessarily represent the views of IDSA. The reader assumes all risks in using this information. The IDSA Hepatitis C Discussion Forum is in full compliance with HIPPA. IDSA bears no responsibility for the accuracy of participant comments and will bear no legal liability for discussion results.

If a participant wishes to post an issue on the IDSA Hepatitis C Discussion Forum, the participant is strongly urged to provide contact information for possible offline discussion via phone or email concerning the posted issue.


RSS Feed Search Category View 
Drug Therapy
  Topics Topic Starter Replies Views Last Post
Gilead gains FDA approval for hep C combo pill ThomasKim 0 6031 Monday, October 13, 2014 12:34 PM 
AbbVie Submits FDA Application for All Oral HCV Therapy tkim@idsociety.org 0 10703 Tuesday, April 22, 2014 1:52 PM 
AbbVie Announces Positive Phase III Results ThomasKim 0 10456 Friday, April 11, 2014 1:52 PM 
Bristol-Myers Squibb Files for FDA Approval of NS5A Drug Combination tkim@idsociety.org 0 10494 Thursday, April 10, 2014 1:50 PM 
Merck Unveils Interim Phase II Results tkim@idsociety.org 0 10578 Thursday, April 10, 2014 1:46 PM 
Gilead Next Generation Combination Pill ThomasKim 0 10808 Monday, March 24, 2014 1:01 PM 
Gilead says payers feel comfortable with the cost of Sovaldi ThomasKim 0 11788 Friday, February 14, 2014 1:06 PM 
Spurred by pricey Gilead hep C drug, payers cook up new cost-control moves tkim@idsociety.org 0 11695 Monday, January 27, 2014 1:44 PM 
Phase III Results for Gilead Hep C Combo tkim@idsociety.org 0 11707 Wednesday, December 18, 2013 12:51 PM 
FDA approves Sovaldi for chronic hepatitis C ThomasKim 0 11816 Monday, December 9, 2013 10:21 AM 
Key hep C protein revealed, paving the way for new vaccines tkim@idsociety.org 0 11727 Wednesday, December 4, 2013 7:57 AM 
Indication and Usage of Olysio (simeprevir) for the Treatment of Chronic Hepatitis C ThomasKim 0 11627 Monday, November 25, 2013 2:38 PM 
J&J, Medivir gain FDA OK for new hep C therapy simeprevir ThomasKim 0 11645 Monday, November 25, 2013 1:08 PM 
AbbVie steps closer to FDA filing as first hep C PhIII delivers promising results tkim@idsociety.org 0 11835 Monday, November 18, 2013 1:45 PM 
FDA Approved Changes to Incivek (telaprevir) Product Labeling to Include OPTIMIZE Trial Results tkim@idsociety.org 0 12194 Wednesday, October 30, 2013 7:56 AM 
Gilead's Sofosbuvir Gains FDA Panel Approval tkim@idsociety.org 0 12144 Monday, October 28, 2013 1:14 PM 
J&J wins FDA panel blessing for hep C blockbuster hopeful ThomasKim 0 11998 Friday, October 25, 2013 2:32 PM 
FDA Internal Review of Sofosbuvir tkim@idsociety.org 0 12174 Wednesday, October 23, 2013 1:21 PM 
Simeprevir Earns Positive Internal Review from FDA ThomasKim 0 12295 Tuesday, October 22, 2013 1:33 PM 
More Drugs Show Promise in Fighting Hepatitis C - HealthDay Article ThomasKim 0 12726 Thursday, August 15, 2013 11:36 AM 
Clinicians Wait for Next Wave of Hepatitis C Antivirals - By: Debra Gordon tkim@idsociety.org 0 14214 Tuesday, June 11, 2013 3:43 PM 
Bristol-Myers gains FDA breakthrough track for HCV drug approval tkim@idsociety.org 0 15070 Thursday, April 25, 2013 2:00 PM 
Gilead applies for FDA approval for Sofosbuvir ThomasKim 0 15100 Tuesday, April 9, 2013 1:36 PM 
J&J, Gilead combo drug therapy clears hep C in 100% of Phase IIa cohort ThomasKim 0 15640 Monday, March 4, 2013 1:00 PM 
Gilead Successfully Completes Fourth Phase III Study tkim 0 15405 Tuesday, February 19, 2013 1:03 PM 
Gilead Passes Two Phase III Test with HCV Pill ThomasKim 0 15427 Monday, February 4, 2013 4:01 PM 
 

| HIVMA | Contact Us

© Copyright IDSA 2016 Infectious Diseases Society of America

Full Site Mobile Site